<DOC>
	<DOCNO>NCT01497860</DOCNO>
	<brief_summary>The purpose study investigate whether weekly Vinorelbine treatment shrink slow growth pediatric low-grade glioma either return continue grow . Vinorelbine semi-synthetic vinca alkaloid recently generate interest patient pediatric low-grade glioma . It specifically synthesize broaden therapeutic spectrum decrease neurotoxicity associate related agent .</brief_summary>
	<brief_title>Vinorelbine Children With Progressive Recurrent Low-grade Gliomas</brief_title>
	<detailed_description>Different treatment exist child progressive recurrent low-grade glioma . Each variable efficacy slow reverse growth , exploration continue find better-tolerated , effective treatment . Vinorelbine recently generate interest stabilize pediatric low-grade glioma . It fairly well tolerate adult pediatric study examine use tumor . Objective : To test efficacy Vinorelbine child pediatric low-grade glioma return continue grow . In trial , Vinorelbine give intravenously week 6 week follow 2 week rest ( 6 every 8 week ) one year . The patient follow 60 month . Progression free survival primary outcome define none following : great 20 % increase sun long diameter target lesion , measurable increase non-target lesion , appearance new lesion .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Age : &lt; 18 year Tumor : Progressive recurrent low grade glioma , WHO grade 1 2 fail least one form 'conventional ' nonsurgical therapy Histologic confirmation require exception optic pathway brain stem glioma . Patients require reoperation time recurrence . Patients disseminate disease eligible . Children neurofibromatosis optic pathway brainstem tumor eligible must definitive radiologic clinical evidence progression Patients must evidence measureable disease Performance status : Karnofsky Lansky performance status &gt; 50 % Organ Function : Adequate bone marrow function ( ANC &gt; 1000/mm3 , platelet count &gt; 75,000/mm3 , hemoglobin &gt; 8gm/dL ) prior start therapy . Hemoglobin may support transfusion Adequate liver function ( SGPT/ALT &lt; 2.5 time ULN bilirubin &lt; 1.5 time ULN ) prior start therapy Prior therapy : May treatment include surgery , chemotherapy , radiotherapy number relapse prior enrollment Patients must receive last fraction radiotherapy &gt; 12 week prior start therapy Previous Vincristine Vinblastine exposure allowable . No significant medical illness investigator ' opinion adequately control appropriate therapy would compromise patient 's ability tolerate therapy Any cancer ( except nonmelanoma skin cancer ) , unless complete remission therapy disease minimum 3 year . Patients childbearing potential must pregnant breastfeeding ( vinorelbine pregnancy category D , data excretion breastmilk ) Patients childbearing father potential must practice adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>pediatric</keyword>
	<keyword>child</keyword>
	<keyword>glioma</keyword>
	<keyword>low-grade</keyword>
	<keyword>vinorelbine</keyword>
	<keyword>recurrent</keyword>
	<keyword>progressive</keyword>
</DOC>